SCHEMBL3674290

SCHEMBL3674290

CC(Cn1c(O)nc2ncc(Cl)cc21)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SRC P12931 7/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.37
KDM4E B2RXH2 1/20 0.37
KDM4A O75164 1/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
RXFP1 Q9HBX9 2/20 0.35
KMO O15229 1/20 0.35
FYN P06241 1/20 0.35
THRB P10828 1/20 0.35
HCK P08631 1/20 0.35
PIM1 P11309 1/20 0.35
PPARG P37231 1/20 0.35
CCR9 P51686 1/20 0.34
GUSB P08236 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3665795 0.89 ALDH1A1 (0.35) ALDH1A1HPGDKDM4EKDM4ATSHR
SCHEMBL3666704 0.83 ALDH1A1 (0.40) ALDH1A1HPGDTSHRHTTHSD17B10
SCHEMBL3669844 0.80 ALDH1A1 (0.53) SRCALDH1A1HPGDKDM4EKDM4A
SCHEMBL3669088 0.80 MEN1 (0.40) ALDH1A1HPGDKDM4ENPSR1HSD17B10
SCHEMBL3675313 0.80 MEN1 (0.40) ALDH1A1HPGDKDM4ENPSR1HSD17B10
SCHEMBL3668883 0.78 HRH4 (0.34) HPGDTSHRHTTHSD17B10GUSB
SCHEMBL3672462 0.77 HRH4 (0.36) HPGDHTTHSD17B10L3MBTL1GUSB
SCHEMBL3672010 0.77 PPARG (0.36) ALDH1A1HPGDKDM4EKDM4ATSHR
SCHEMBL3668071 0.76 HPGD (0.38) HPGDKDM4EHTTHSD17B10RXFP1
SCHEMBL3667745 0.75 BRD4 (0.40) SRCALDH1A1HPGDKDM4EKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US claimed
EP-2139478-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS Cytokinetics, Incorporated (US) 2010-01-06 EP claimed
WO-2008121333-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-10-09 WO claimed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US claimed
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US disclosed
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US disclosed
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US disclosed
EP-2139478-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS Cytokinetics, Incorporated (US) 2010-01-06 EP disclosed
WO-2008121333-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-10-09 WO disclosed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US disclosed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US disclosed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods TNNC1, TNNI3, TNNT2 SRC 2518/4885ALDH1A1 4750/4885HPGD 3712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.